Olsar (Olmesartan Medoxomil)

Olmesartan medoxomil, the active ingredient in Olsar, is an angiotensin II receptor blocker presented as a tablet for oral use. It treats hypertension and is indicated for use in adults. GNH USA supplies Olsar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Olsar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan medoxomil is an antihypertensive agent that works within the renin‑angiotensin‑aldosterone system to lower blood pressure.

- Hypertension: helps achieve target blood pressure levels in adult patients. - Heart failure: used as part of combination therapy to improve cardiac function. - Diabetic nephropathy: provides renal protection by reducing intraglomerular pressure.

Olmesartan medoxomil may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dizziness - Headache - Fatigue - Nasal congestion - Diarrhea

Serious or Rare Side Effects: - Angio‑ema - Hyperkalemia - Acute kidney injury - Severe hypotension - Liver enzyme elevation

When prescribing Olmesartan medoxomil, clinicians should consider several safety aspects.

- Monitor blood pressure: ensure adequate control without excessive lowering. - Assess renal function: adjust use in patients with impaired kidney function. - Check electrolytes: watch for potassium abnormalities. - Avoid in pregnancy: drug is contraindicated during the second and third trimesters. - Review concomitant medications: consider potential additive blood‑pressure effects. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Olmesartan medoxomil can interact with other medicines that affect blood pressure or renal function.

Major Interactions (Avoid): - Dual renin‑angiotensin system blockade (e.g., ACE inhibitors, other ARBs). - Potassium‑sparing diuretics or supplements (risk of hyper‑kalemia).

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs) may reduce antihypertensive effect. - Lithium: may increase lithium levels. - Cyclosporine or tacrolimus: may worsen renal function. - Diuretics: may enhance hypotensive response. - Antacids containing aluminium or magnesium: may affect absorption.